Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Feb 15:8:06.
doi: 10.18332/tpc/146645. eCollection 2022.

Lung cancer in Europe: The way forward

Monica Racovita  1 , Eleanor Wheeler  1 , Suzanne Wait  1 , Dani Bancroft  1 , Rowan Eastabrook  1 , Tit Albreht  2   3 , Anne-Marie Baird  4   5 , Jacek Jassem  6 , Aoife McNamara  7   8 , Silvia Novello  9   10 , Cornel Radu-Loghin  11 , Jan P van Meerbeeck  12   13   14
Affiliations
Editorial

Lung cancer in Europe: The way forward

Monica Racovita et al. Tob Prev Cessat. .
No abstract available

Keywords: COVID-19; Europe; lung cancer; non-communicable diseases; screening; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors have each completed and submitted an ICMJE Form for Disclosure of Potential Conflicts of Interest. M. Racovita, E. Wheeler, S. Wait, D. Bancroft, and R. Eastabrook (The Health Policy Partnership) report fees from AstraZeneca, Johnson & Johnson, Elekta, and Philip , related to the current work, and funds from Amgen, AstraZeneca, Bristol Myers Squibb (BMS), Johnson & Johnson, Novartis, Advanced Accelerator Applications, Roche Diagnostics, Sanofi, GE Healthcare, Elekta, Vifor Pharma, UCB, Pfizer, Boehringer Ingelheim, and Philips, outside the submitted work. J. Jassem reports fees from AstraZeneca, MSD, and Exact Sciences, outside the submitted work. S. Novello reports consulting fees from BMS, Eli LILLY, Takeda, ROCHE, Pfizer, Astrazeneca, BI, MSD, Abbvie, Pharmamar, and Beigene, outside the submitted work. A. M. Braid reports consulting fees from Lungevity and honoraria from Roche, outside the submitted work. The rest of the authors have nothing to disclose.

References

    1. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer; 2020. Updated December 1, 2020. Accessed November 25, 2021. https://gco.iarc.fr/today.
    1. Islami F, Torre LA, Jemal A. Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res. 2015;4(4):327–338. doi: 10.3978/j.issn.2218-6751.2015.08.04. - DOI - PMC - PubMed
    1. Tindle HA, Stevenson Duncan M, Greevy RA, et al. Lifetime Smoking History and Risk of Lung Cancer: Results From the Framingham Heart Study. J Natl Cancer Inst. 2018;110(11):1201–1207. doi: 10.1093/jnci/djy041. - DOI - PMC - PubMed
    1. Myers R, Brauer M, Dummer T, et al. High-Ambient Air Pollution Exposure Among Never Smokers Versus Ever Smokers With Lung Cancer. J Thorac Oncol. 2021;16(11):1850–1858. doi: 10.1016/j.jtho.2021.06.015. - DOI - PubMed
    1. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020;382(6):503–513. doi: 10.1056/NEJMoa1911793. - DOI - PubMed

Publication types